Login to Your Account



Oncothyreon's breast cancer phase Ib results confuse, later gladden

By Randy Osborne
Staff Writer

Wednesday, December 9, 2015

A complex dataset from the ongoing clinical work with ONT-380 in HER2-positive metastatic breast cancer served mainly to ferhoodle Oncothyreon Inc. investors, and the stock lost 32 percent Wednesday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription